Semaglutide vs Retatrutide: Metabolic Peptide Comparison

Semaglutide and retatrutide represent two generations of metabolic peptide research. Semaglutide is a single-target GLP-1 receptor agonist with a 165-hour half-life and extensive clinical validation. Retatrutide is a next-generation triple agonist simultaneously engaging GLP-1, GIP, and glucagon receptors. Researchers comparing these compounds are evaluating single-receptor versus multi-receptor metabolic approaches.